Icosavax jumps on promising data update for RSV vaccine trial

Icosavax

13/12/2022 21:56

** Shares of biopharma company Icosavax Inc  ICVX.O  gain
~10% to $4.63 after market 
    ** Company provides data update from early-stage trial of
its experimental respiratory syncytial virus (RSV) vaccine
IVX-121 
    ** Says data showed sustained neutralizing antibody response
against RSV, lasting for at least six months after a single
administration of IVX-121 
    ** IVX-121 continued to be generally well-tolerated with no
safety concerns observed in the six-month follow up, the company
said
    ** Company plans to provide 12-month update from an
extension of the trial in mid-2023
    ** As of last close, stock down ~82% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com))